QuickLinks -- Click here to rapidly navigate through this document

SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549

FORM 8-K

CURRENT REPORT
Pursuant To Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 13, 2002

Array BioPharma Inc.
(Exact name of registrant as specified in its charter)

Delaware   000-31979   84-1460811
(State or Other Jurisdiction
of Incorporation)
  (Commission
File Number)
  (IRS Employer
Identification No.)

 

 

 

 

 
3200 Walnut Street, Boulder, Colorado   80301
(Address of Principal Executive Offices)   (Zip Code)

Registrant's telephone number, including area code: (303) 381-6600

(Former Name or Former Address, if Changed Since Last Report)



ITEM 9. REGULATION FD DISCLOSURE

        The Registrant hereby furnishes, and attaches as Exhibits 99.1 and 99.2 hereto, the certifications required pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

2



SIGNATURES

        Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


 

 

ARRAY BIOPHARMA INC.

Date: November 13, 2002

 

By:

 

/s/  
ROBERT E. CONWAY      
Robert E. Conway
Chief Executive Officer

3


Exhibit No.

   
99.1   Written Certification of Robert E. Conway pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

99.2

 

Written Certification of R. Michael Carruthers pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.



QuickLinks

SIGNATURES